MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

December 4, 2025

Study Completion Date

December 10, 2025

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

MAS-1 adjuvanted Insulin B-chain

MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.

Trial Locations (1)

80045

RECRUITING

University of Colorado, Denver, Aurora

Sponsors
All Listed Sponsors
collaborator

The Leona M. and Harry B. Helmsley Charitable Trust

OTHER

collaborator

Nova Immunotherapeutics Limited

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT03624062 - MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes | Biotech Hunter | Biotech Hunter